Amylyx Pharma Q3 loss narrows

Amylyx Pharmaceuticals

06/11/2025 12:20

Overview

Amylyx Q3 net loss narrows, beating analyst expectations for EPS and net income

Company's cash position strengthened by $191 mln public offering, extending runway into 2028

Completion of recruitment for Phase 3 LUCIDITY trial expected in Q1 2026

Outlook

Company expects to complete recruitment for Phase 3 LUCIDITY trial in Q1 2026

Topline data from LUCIDITY trial anticipated in Q3 2026

Commercial launch of avexitide anticipated in 2027, if approved

Result Drivers

Research and development expenses for the third quarter of 2025 were $19.9 million, compared to $21.2 million for the same period in 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
Beat
-$0.37
-$0.47 (7 Analysts)
Q3 Net Income
Beat
-$34.39 mln
-$41.60 mln (8 Analysts)
Q3 Operating Income
Beat
-$36.03 mln
-$43.10 mln (9 Analysts)
Q3 Pretax Profit
Beat
-$34.39 mln
-$42.50 mln (6 Analysts)
Q3 Operating Expenses
$36.03 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Amylyx Pharmaceuticals Inc is $19.00, about 30.3% above its November 5 closing price of $13.24

Press Release: ID:nBw1MCSvVa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)